Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

BACKGROUND: Cetuximab can reverse chemotherapy resistance in colorectal cancer. This study evaluated the efficacy and safety of the combination of docetaxel and cetuximab as a second-line treatment in docetaxel-refractory oesophagogastric cancer. METHODS: Patients received docetaxel 30 mg m(−2) on d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tebbutt, N C, Parry, M M, Zannino, D, Strickland, A H, Van Hazel, G A, Pavlakis, N, Ganju, V, Mellor, D, Dobrovic, A, Gebski, V J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3590676/
https://ncbi.nlm.nih.gov/pubmed/23412099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.41
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados